Cargando…

Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC

INTRODUCTION: To assess impact of glycemic control on plasma protein-bound advanced glycation end products (pAGEs) and their association with subsequent microvascular disease. RESEARCH DESIGN AND METHODS: Eleven pAGEs were measured by liquid chromatography-mass spectrometry in banked plasma from 466...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monnier, Vincent M, Sell, David R, Gao, Xiaoyu, Genuth, Saul M, Lachin, John M, Bebu, Ionut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Pathophysiology/Complications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783825/ https://www.ncbi.nlm.nih.gov/pubmed/35058313 http://dx.doi.org/10.1136/bmjdrc-2021-002667

Ejemplares similares

Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes
por: Genuth, Saul, et al.
Publicado: (2015)

Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications
por: Lopes-Virella, Maria F., et al.
Publicado: (2008)

Relationship of Glycated Albumin to Blood Glucose and HbA(1c) Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study
por: Nathan, David M., et al.
Publicado: (2014)

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
por: Lachin, John M., et al.
Publicado: (2017)

Relationship of Urologic Complications With Health-Related Quality of Life and Perceived Value of Health in Men and Women With Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Interventions and Complications (DCCT/EDIC) Cohort
por: Jacobson, Alan M., et al.
Publicado: (2015)

Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
por: Polak, Joseph F., et al.
Publicado: (2011)

Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study
por: Bebu, Ionut, et al.
Publicado: (2020)

Serum urate and cardiovascular events in the DCCT/EDIC study
por: Jenkins, Alicia J., et al.
Publicado: (2021)

Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
por: Bebu, Ionut, et al.
Publicado: (2019)

Biomarkers of tubulointerstitial damage and function in type 1 diabetes
por: de Boer, Ian H, et al.
Publicado: (2017)

Coronary Artery Disease Events and Carotid Intima‐Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort
por: Polak, Joseph F., et al.
Publicado: (2021)

The Impact of Salsalate Treatment on Serum Levels of Advanced Glycation End Products in Type 2 Diabetes
por: Barzilay, Joshua I., et al.
Publicado: (2014)

Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC
Publicado: (2015)

OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience
por: Molitch, Mark, et al.
Publicado: (2019)

Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study
por: Darabian, Sirous, et al.
Publicado: (2016)

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
por: Braffett, Barbara H., et al.
Publicado: (2019)

Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC
por: Genuth, Saul M., et al.
Publicado: (2013)

A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes: Data from the Diabetes Control and Complications Trial
por: Kilpatrick, Eric S., et al.
Publicado: (2008)

Lower levels of 25-hydroxyvitamin D(3) are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes
por: Zoppini, Giacomo, et al.
Publicado: (2015)

Glycation by glyoxal leads to profound changes in the behavior of dermal fibroblasts
por: Guillon, Cécile, et al.
Publicado: (2021)

Diminished Alveolar Microvascular Reserves in Type 2 Diabetes Reflect Systemic Microangiopathy
por: Chance, William W., et al.
Publicado: (2008)

Two-year longitudinal trajectory patterns of albuminuria and subsequent rates of end-stage kidney disease and all-cause death: a nationwide cohort study of biopsy-proven diabetic kidney disease
por: Yamanouchi, Masayuki, et al.
Publicado: (2021)

Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes
por: Oshima, Megumi, et al.
Publicado: (2021)

Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC)
por: Lachin, John M., et al.
Publicado: (2021)

Burden of Urological Complications in Men and Women With Long-standing Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort
por: Wessells, Hunter, et al.
Publicado: (2018)

RUNX1 can mediate the glucose and O-GlcNAc-driven proliferation and migration of human retinal microvascular endothelial cells
por: Xing, Xindan, et al.
Publicado: (2021)

Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study
por: Tang, W.H. Wilson, et al.
Publicado: (2018)

Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial
por: Lin, Julie, et al.
Publicado: (2008)

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664
por: Braffett, Barbara H., et al.
Publicado: (2019)

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
por: Soliman, Elsayed Z., et al.
Publicado: (2017)

Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy
por: Skupien, Jan, et al.
Publicado: (2019)

Microscopic hematuria is a risk factor for end-stage kidney disease in patients with biopsy-proven diabetic nephropathy
por: Okada, Sadanori, et al.
Publicado: (2020)

The Association of Skin Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study
por: Orchard, Trevor J., et al.
Publicado: (2013)

Circulating Levels of Adipocyte and Epidermal Fatty Acid–Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients
por: Yeung, Dennis C.Y., et al.
Publicado: (2009)

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
por: Gubitosi-Klug, Rose A., et al.
Publicado: (2017)

Correlation of global risk assessment with cardiovascular complications in patients with diabetes mellitus living in Puerto Rico
por: Rodríguez-Vigil, Efraín, et al.
Publicado: (2016)

Effects of modified lipoproteins on human trophoblast cells: a role in pre-eclampsia in pregnancies complicated by diabetes
por: McLeese, Rebecca Helen, et al.
Publicado: (2021)

Novel Subgroups of Type 2 Diabetes Display Different Epigenetic Patterns That Associate With Future Diabetic Complications
por: Schrader, Silja, et al.
Publicado: (2022)

Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population
por: Song, Soon H
Publicado: (2015)

Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes
por: Liu, Jian-Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bnsc08b086hdheln7rvvqm5vma